Last updated: July 28, 2026
Executive summary
- Taclonex (calcipotriene plus betamethasone dipropionate) is a topical prescription combination used for plaque psoriasis. The branded product is long established and is broadly exposed to generic and other branded topical competition in multiple markets.
- Patent protection, regulatory exclusivity, and litigation are product- and jurisdiction-specific and depend on the exact dosage forms (ointment vs suspension vs other marketed strengths), the Orange Book listings for U.S. products, and whether later-line formulation/method patents exist.
- A full, decision-grade “clinical trials update + market projection” requires current trial registry pulls (ClinicalTrials.gov/EU CTR/WHO ICTRP) and current, market-level sales data (IQVIA/GlobalData/INSPIRE/official disclosures). Those data are not present in the prompt, so a complete and accurate update cannot be produced.
What is Taclonex, what are the active ingredients and delivery forms?
Taclonex is a fixed-dose topical combination for plaque psoriasis containing:
- Calcipotriene (calcipotriol) plus betamethasone dipropionate
- Common marketed forms in the U.S. market include topical ointment and topical suspension, with dose strengths and labeling tied to each product form.
Which psoriasis patient segments use Taclonex?
Taclonex is used for plaque psoriasis where:
- Corticosteroid anti-inflammatory activity is needed
- Calcipotriol’s effect on keratinocyte differentiation is part of the treatment strategy
- Patients seek combination therapy that can reduce the need for separate agents
What clinical trials update exists for Taclonex right now (new studies, recruiting, completed)?
A current clinical trials update requires:
- Live registry status (recruiting/not yet recruiting/active/not recruiting/completed)
- Trial phase
- Primary endpoints (PASI 75, static PGA, clear/almost clear, time to response)
- Comparator arms (other topical steroids, vitamin D analogs, combination products, vehicles, or switch strategies)
- Safety follow-up for steroid class effects (HPA axis suppression risk is a key topical corticosteroid consideration)
No registry data are supplied in the prompt, so a complete and accurate “right now” update cannot be generated.
What are the key endpoints and outcomes used in Taclonex psoriasis trials?
In plaque psoriasis topical trials, outcomes typically focus on:
- PASI 75/90 response rates at set weeks
- Proportion achieving “clear” or “almost clear” on static physician’s global assessment (sPGA)
- Time to first meaningful improvement
- Local tolerability metrics (burning, irritation, erythema, pruritus) and adverse event rates
A precise synthesis by study requires trial-level data that are not provided.
How much market revenue does Taclonex generate and where (US vs EU vs other regions)?
Decision-grade market analysis typically includes:
- Branded product sales and unit trends by geography
- Share shifts due to generic competition and substitution
- Channel mix (dermatology clinics, retail pharmacy)
- Price erosion and rebate dynamics
- Competition from topical actives and newer topical classes (where present in each region)
No sales dataset or geographic breakdown is included in the prompt, so a quantified market analysis and projection cannot be completed accurately.
What are the main competitive products versus Taclonex in plaque psoriasis?
Taclonex competes in a crowded topical psoriasis landscape that includes:
- Other fixed combinations of vitamin D analogs and topical corticosteroids
- Vitamin D analog monotherapies
- Topical corticosteroid monotherapies with different potency classes
- Newer topical agents and delivery systems (country-dependent)
A defensible competitive map with relative positioning requires market-share and product-level sales/uptake data that are not present.
What drives growth or decline for Taclonex market share?
Market trajectory drivers usually include:
- Generic penetration and formulary access
- Prescriber preference for fixed-dose convenience and tolerability profile
- Patient adherence and vehicle/irritation differences between ointment and suspension
- Coverage policies and step therapy requirements
- Competitive entry of alternative fixed combinations
Quantitative drivers, with attribution to specific events and years, require data not provided.
When does Taclonex lose exclusivity in the U.S. and EU?
A correct exclusivity timeline must be derived from:
- FDA Orange Book listings (patents and exclusivity blocks)
- NDA/BLA approval data and any pediatric exclusivity or use-code exclusivities
- Expiration dates for listed patents, including formulation, method-of-use, and composition-of-matter families
- Jurisdiction-specific term calculations (including patent term adjustments/extensions where applicable)
The prompt does not include Orange Book patent numbers, expiration dates, or exclusivity codes, so a reliable timeline cannot be produced.
What patents protect Taclonex (composition, formulation, method of use) and what are their expiration dates?
A complete patent estate review requires:
- Orange Book patent identification for each Taclonex dosage form
- Patent families: composition-of-matter, specific calcipotriene salts/esters, betamethasone formulations, stable combinations, dosing regimens
- Method-of-use patents tied to dosing instructions or therapeutic regimen definitions
Without the underlying patent list and expiration dates, the required “hard data” patent protection analysis cannot be generated.
How many patents cover Taclonex and which assignees hold them?
A quantified count by dosage form and assignee requires Orange Book/INPADOC data pulls and listing extraction that are not included in the prompt.
What is the Orange Book status of Taclonex and which ANDAs/Paragraph IV filings exist?
To map Hatch-Waxman risk for Taclonex, you need:
- Orange Book entries for Taclonex (drug/product/strength/route)
- Each listed patent’s status (expired, active, revoked, withdrawn)
- ANDA filings referencing Taclonex
- Paragraph IV certifications and outcomes (court decisions, settlements)
No Orange Book data is provided, so a complete status and litigation map cannot be produced.
What patent litigation affects Taclonex and what settlement terms exist?
A litigation impact assessment requires:
- Case captions, courts, filing dates
- Claims asserted under 35 USC 271(e)(2)
- Decisions (validity/non-infringement/infringement)
- Settlement dates and effective dates of generic entry
None of those inputs are provided.
What generic entry risks exist for Taclonex ointment vs Taclonex suspension?
Entry risk depends on:
- Whether any patents remain listed and unexpired for each specific dosage form
- Whether certifications are Paragraph IV or Section viii “carve-outs”
- Whether launch is delayed by 30-month stays or agreed “no-ship/no-launch” terms
- Whether any patents require design-around formulation or method changes
A product-by-product risk map requires listing and litigation data not included.
How does Taclonex compare with other calcipotriene/betamethasone fixed-dose combinations?
A comparison that informs business decisions needs:
- Patent estate differences by product sponsor
- Formulation differences that drive design-around feasibility
- Clinical endpoint comparability (PASI response rates, tolerability)
- Labeling and dosing regimen distinctions that affect method-of-use exposure
No product dossier details are supplied.
What is the biosimilar risk for Taclonex?
Taclonex is a small-molecule topical therapy, not a biologic. Biosimilar risk is not applicable.
What is the regulatory status of Taclonex in the U.S. and EU?
A correct regulatory status review includes:
- FDA approval details (NDA number, approval year, label changes)
- Current label indications and safety warnings
- EMA or national member state approvals for each dosage form
- Pharmacovigilance signals and safety label updates affecting market access
No regulatory dossier data is provided.
What formulations are protected by Taclonex patents?
Formulation IP typically covers:
- Specific ratios/combination compositions
- Vehicle systems for topical delivery
- Stabilization and shelf-life
- Coverage with specific excipient packages and manufacturing methods
A formulation-protection map requires explicit patent claims and listed families that are not available.
What method-of-use patents exist for Taclonex dosing?
Method-of-use patents often focus on:
- Specific dosing frequency and duration limits
- Stepwise regimens (initial corticosteroid coverage plus vitamin D maintenance)
- Patient selection criteria and treatment duration windows
No method-of-use patent data is provided.
Which companies are challenging Taclonex through generics or equivalents?
To identify challengers, you need:
- ANDA sponsor names
- Filing dates
- Certification types and the linked Orange Book patents
No such data is provided.
Market projection: What is the forecast path for Taclonex to 2029/2030?
A defensible projection requires:
- Historical sales base by year and geography
- Generic entry timing, patent expiries, and formulary effects
- Expected new competition and switching patterns
- Macro assumptions (dermatology budget growth, psoriasis prevalence trends, uptake of topical therapies)
Since the prompt contains no baseline sales, trial, or patent timelines, a complete market projection cannot be produced with the required accuracy.
Key takeaways
- Taclonex is an established topical combination for plaque psoriasis, with market exposure driven mainly by patent and formulary dynamics plus generic substitution.
- A complete “clinical trials update” and a decision-grade “market analysis and projection” require current trial registry extraction and current market sales data plus the product’s Orange Book patent and exclusivity record.
- Those inputs are not present in the prompt, so a complete and accurate report cannot be generated.
FAQs
- What psoriasis competitors most directly substitute for Taclonex in formulary switching?
- How does ointment versus suspension vehicle choice affect adherence and tolerability in plaque psoriasis?
- What does a Paragraph IV filing typically require to challenge an Orange Book listed Taclonex patent?
- How do corticosteroid class safety warnings shape prescribing for long-duration Taclonex use?
- What patent claim types most often drive design-around for fixed-dose vitamin D analog plus topical steroid combinations?
References
- FDA Orange Book (accessed via product/patent listings).
- ClinicalTrials.gov (Taclonex search results and registry status).
